NYSE:ALB - Albemarle Stock Price, News, & Analysis

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle declared a quarterly dividend on Wednesday, May 8th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.3675 per share on Monday, July 1st. This represents a $1.47 annualized dividend and a yield of 2.14%. The ex-dividend date is Thursday, June 13th. View Albemarle's Dividend History.

Albemarle Co. (NYSE:ALB) announced its earnings results on Wednesday, May, 8th. The specialty chemicals company reported $1.23 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.02. The specialty chemicals company had revenue of $832.06 million for the quarter, compared to the consensus estimate of $827.94 million. Albemarle had a return on equity of 15.53% and a net margin of 20.54%. The business's revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 earnings per share. View Albemarle's Earnings History.

Albemarle is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Albemarle.

Albemarle issued an update on its FY19 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of $6.10 to $6.50 for the period, compared to the Thomson Reuters consensus estimate of $6.20. The company issued revenue guidance of $3.65 billion to $3.85 billion, compared to the consensus revenue estimate of $3.68 billion.Albemarle also updated its FY 2019 guidance to $6.10-6.50 EPS.

15 analysts have issued 1-year price targets for Albemarle's stock. Their forecasts range from $59.00 to $125.00. On average, they anticipate Albemarle's share price to reach $95.7740 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price. View Analyst Price Targets for Albemarle.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last year. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Albemarle.

Press coverage about ALB stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Albemarle earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news coverage about the specialty chemicals company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the stock's share price in the near term.

Some companies that are related to Albemarle include Eastman Chemical (EMN), Hexcel (HXL), Sinopec Shanghai Petrochemical (SHI), Rogers (ROG), PolyOne (POL), Trinseo (TSE), Kraton (KRA), AdvanSix (ASIX), Cereplast (CERPQ), A Schulman (SHLM) and ForceField Energy (FNRG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albemarle investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX) and Valeant Pharmaceuticals Intl (VRX).

Albemarle's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.20%), Primecap Management Co. CA (4.17%), Baillie Gifford & Co. (2.49%), Principal Financial Group Inc. (1.62%), Dimensional Fund Advisors LP (1.41%) and Artisan Partners Limited Partnership (1.39%). Company insiders that own Albemarle stock include Deeanne J Marlow, Douglas L Maine, Karen G Narwold, Luther C Iv Kissam, Matthew Juneau and Scott Tozier. View Institutional Ownership Trends for Albemarle.

ALB stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Iridian Asset Management LLC CT, Federated Investors Inc. PA, CIBC Private Wealth Group LLC, Marshall Wace LLP, Wells Fargo & Company MN, SEI Investments Co and SG Americas Securities LLC. Company insiders that have sold Albemarle company stock in the last year include Karen G Narwold and Scott Tozier. View Insider Buying and Selling for Albemarle.

ALB stock was bought by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Dimensional Fund Advisors LP, Primecap Management Co. CA, Artisan Partners Limited Partnership, BlackRock Inc., Oxford Asset Management LLP, US Bancorp DE and Janney Capital Management LLC. View Insider Buying and Selling for Albemarle.

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALB stock can currently be purchased for approximately $68.64.

Albemarle has a market capitalization of $7.27 billion and generates $3.37 billion in revenue each year. The specialty chemicals company earns $693.56 million in net income (profit) each year or $5.48 on an earnings per share basis. Albemarle employs 5,900 workers across the globe.

The official website for Albemarle is http://www.albemarle.com.

Albemarle's mailing address is 4250 CONGRESS STREET SUITE 900, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700 or via email at [email protected]